Cullinan Oncology, Inc. (NASDAQ: CGEM) reported Q3 EPS of ($0.54), $0.43 better than the analyst estimate of ($0.97). Revenue for the quarter came in at $0 versus the consensus estimate of $0 .

For earnings history and earnings-related data on Cullinan Oncology, Inc. (CGEM) click here.